Register with MSD Connect
✔ Sign up for events
✔ Complete learning modules
✔ Receive cancer resources
✔ Access additional content
KEYNOTE-024 data presentation: KEYTRUDA® (pembrolizumab) vs. chemotherapy for PD-L1-positive non-small cell lung cancer
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
PDF, 5.28 MB
Download our KEYNOTE-024 slide deck that discusses KEYTRUDA vs chemotherapy for PD-L1-positive non-small cell lung cancer.
More information about KEYTRUDA in metastatic NSCLC:
Supporting documentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website.
